INTERIM Confirms 5-Year Efficacy of Intermittent Imatinib in CML
Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Ponatinib Shows Promise in CML Even After Early Trial Termination
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
Proteasome Inhibitor May Benefit Difficult-to-Treat Myeloma Patients
A new, investigational proteasome inhibitor, oprozomib (Onyx Pharmaceuticals, Inc.), has shown activity in multiple myeloma, including those patients with carfilzomib-refractory disease.
Cyclin-Dependent Kinase Inhibitor for CLL
Combining the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) with ofatumumab (Arzerra) resulted in activity in relapsed or refractory chronic lymphocytic leukemia (CLL).
Ibrutinib Shows Activity in Multiple Myeloma
Heavily pretreated multiple myeloma patients responded to treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (Imbruvica) plus dexamethasone in a phase 2, open-label, dose-finding trial.
Daratumumab Safe With Myeloma Backbone Therapies
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
Novel Targeted Agent Shows Promise in Acute Myeloid Leukemia
An oral inhibitor of isocitrate dehydrogenase 2 (IDH2), AG-221, has shown activity and potentially durable remissions in patients with acute myeloid leukemia.
By clicking Accept, you agree to become a member of the UBM Medica Community.